Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.41 USD
Change Today 0.00 / 0.00%
Volume 765.0
ULUR On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

4452 Beltway Drive

Addison, TX 75001

United States

Phone: 214-905-5145

Fax: 214-905-5130

ULURU Inc., a specialty pharmaceutical company, engages in developing and commercializing a range of wound care and mucoadhesive film products based on its patented Nanoflex and OraDisc technologies with the target of improving outcomes for patients, health care professionals, and health care payers. Marketed Products The company has used its drug delivery technology platforms to develop the following products and product candidates: Altrazeal Altrazeal Transforming Powder Dressing, based on the company’s Nanoflex technology, has the potential to change the way health care providers approach their treatment of wounds. The product is indicated for exuding wounds, such as partial thickness burns, donor sites, abrasions, non-healing surgical wounds, trauma, and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The powder fills and seals the wound to provide an optimal moist wound healing environment. The wound exudate is controlled through the high moisture vapor transpiration rate of the material generated by capillary forces that creates a low pressure environment at the wound bed, which supports cellular function and tissue repair, and holds the dressing in place. The focus of the company’s commercial activities is introducing Altrazeal in all major international markets through its network of distribution partners. Due to the efforts of two of the company’s licensees, Altrazeal Trading GmbH and Altrazeal AG, Altrazeal is available in Australia, Austria, Croatia, the Czech Republic, Portugal, Slovakia, Slovenia, and South Africa. During 2014, the company is expecting the launch and availability of Altrazeal in 20 new international markets. The company has a licensing and supply agreement with Jiangxi Aiqilin Pharmaceuticals Group Company, a corporation in China (Aiqilin), for the development and commercialization of Altrazeal in China, including Hong Kong, Macau, and Taiwan. Aiqilin has also been granted certain manufacturing rights. The agreement covers Altrazeal, Altrazeal Silver, and Altrazeal Collagen. The company also has a license and supply agreement with Melmed Holding AG for marketing Altrazeal throughout the European Union, Australia, New Zealand, North Africa, and the Middle East. In September 2013, the company executed a license and supply agreement with Altrazeal AG (the ‘AG Agreement’) to market Altrazeal in various territories, to include Africa (markets not already licensed), Latin America, Georgia, Turkmenistan, Ukraine, and the Commonwealth of Independent States. In October 2013 and February 2014, the company executed amendments to the AG Agreement for the purpose of expanding the territories to include Asia and the Pacific (excluding China, Hong Kong, Macau, Taiwan, South Korea, Japan, Australia, and New Zealand), Jordan, and Syria. Aphthasol (Amlexanox 5% Paste) Aphthasol, amlexanox 5% paste, is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of canker sores. Marketing authorization for amlexanox 5% paste in the United Kingdom is received. Approval to market is granted in Austria, Germany, Greece, Finland, Ireland, Luxembourg, the Netherlands, Norway, Portugal, and Sweden. The therapeutic Products Programme, the Canadian equivalent of the FDA, has issued a notice of compliance permitting the sale of amlexanox 5% paste, called Apthera, in Canada by Pharmascience Inc., the company’s Canadian partner. In addition to the company’s license agreement with Meda AB, Sweden, licensing agreements have been executed with Laboratories Esteve for Spain, Portugal, and Greece; Pharmascience Inc. for Canada; EpiTan, Ltd. for Australia and New Zealand; Orient Europharma, Co., Ltd for Taiwan, Hong-Kong, the Philippines, Thailand, and Singapore; and KunWha Pharmaceutical Co., Ltd for South Korea. Contract Pharmaceuticals Ltd., Canada is the company’s contract manufacturer for various markets, including the United States. OraDisc A The company has developed a novel adhesive film product that is bioerodible. This technology, known as OraDisc, comprises a multi-layered film having an adhesive layer,

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULUR:US $0.41 USD 0.00

ULUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $157.68 USD +1.29
Smith & Nephew PLC 1,143 GBp +26.00
View Industry Companies
 

Industry Analysis

ULUR

Industry Average

Valuation ULUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.6x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ULURU INC, please visit www.uluruinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.